Treatment decision for prostate cancer with an intermediate risk level
The following parameters indicate prostate cancer with an intermediate level of risk: tumour category cT2b or Gleason score 7 or PSA >10-20 ng/ml.
Radical prostatectomy
The following parameters indicate prostate cancer with an intermediate level of risk: tumour category cT2b or Gleason score 7 or PSA >10-20 ng/ml.
Surgical removal of the prostate (radical prostatectomy – RPE) is a first-line treatment option for patients with a clinically localised prostate carcinoma in all risk groups.
Radiotherapy
Radiotherapy can also be a suitable first-line treatment for all risk groups. Radiotherapy administered externally (percutaneously) can also be supplemented with HDR brachytherapy.
HDR brachytherapy
Brachytherapy is a form of internal radiotherapy. It can be administered as low-dose rate (LDR) or high-dose rate (HDR) brachytherapy. HDR brachytherapy involves temporary implantation of a high-dose radiation source and can be used against moderately and highly aggressive tumours. In HDR brachytherapy, a radiation source is implanted under anaesthetic and then removed a few minutes later. This procedure is repeated one week later and is usually accompanied by percutaneous radiotherapy.
Focal treatment
In most patients with a prostate carcinoma, the entire prostate has to be treated. This is because, in over 80% of cases, numerous tumour lesions are distributed throughout the entire prostate. However, if the tumour is unifocal (limited to a single lesion) or confined to a specific area (e.g. a lateral lobe), and if your PSA level is below 15 ng/ml, it can be removed in a selective, targeted procedure without having to remove the entire prostate.
Treatment decisions when prostate cancer is detected early
Treatment decisions for high-risk prostate cancer
What treatment options are available for low-risk prostate cancer?
The following parameters indicate prostate cancer with an intermediate level of risk: tumour category cT2b or Gleason score 7 or PSA >10-20 ng/ml.
Surgical removal of the prostate (prostatectomy) is a first-line treatment option for patients with a clinically localised prostate carcinoma in all risk groups. Radiotherapy can also be a suitable first-line treatment for all risk groups. Radiotherapy administered externally (percutaneously) can be supplemented with HDR brachytherapy. If the tumour is contained in a specific area, localised removal of the tumour lesion (focal treatment) may also be an option.